Differences in results between image reads performed at a clinical trial site and blinded independent central reviews (BICR) are often termed “site/central discordance”. In many trials, these differences raise concerns among sponsors and regulators and even result in overall trial failure. While it is usually the results of the BICR which determine imaging endpoints, regulators are very interested in the site read results to ensure an acceptable level of congruence.

This presentation will cover all you need to know about site/central discordance in cancer trials including:

• Why does discordance occur and how is it detected?
• What is acceptable discordance?
• If you find discordance, what’s next?
• How can Discordance be reduced?

Bring your problems with discordance issues and we will discuss.